LTC1687329I2 - Optimizuotos HPV58 L1 raiška mielėse - Google Patents

Optimizuotos HPV58 L1 raiška mielėse

Info

Publication number: LTC1687329I2
Authority: LT; Lithuania
Prior art keywords: yeast; expression; hpv58; optimized; optimized hpv58
Prior art date: 2003-11-12

Application number

LTPA2015048C

Other languages

English (en)

Original Assignee

Merck Sharp & Dohme Corp.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-12

Filing date

2015-12-08

Publication date

2017-05-10

2015-12-08 Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.

2017-05-10 Publication of LTC1687329I2 publication Critical patent/LTC1687329I2/lt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
Zoology (AREA)
Biotechnology (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

LTPA2015048C 2003-11-12 2015-12-08 Optimizuotos HPV58 L1 raiška mielėse LTC1687329I2 (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51921103P	2003-11-12	2003-11-12
PCT/US2004/037372 WO2005047315A2 (en)	2003-11-12	2004-11-10	Optimized expression of hpv 58 l1 in yeast

Publications (1)

Publication Number	Publication Date
LTC1687329I2 true LTC1687329I2 (lt)	2017-05-10

Family

ID=34590374

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTPA2015048C LTC1687329I2 (lt)	2003-11-12	2015-12-08	Optimizuotos HPV58 L1 raiška mielėse

Country Status (32)

Country	Link
US (2)	US7498036B2 (lt)
EP (1)	EP1687329B8 (lt)
JP (2)	JP4912885B2 (lt)
KR (1)	KR101170654B1 (lt)
CN (1)	CN1942583B (lt)
AR (1)	AR046835A1 (lt)
AT (1)	ATE452977T1 (lt)
AU (1)	AU2004290032B2 (lt)
BE (1)	BE2015C070I2 (lt)
BR (1)	BRPI0416393B1 (lt)
CA (1)	CA2543928C (lt)
CY (2)	CY1113875T1 (lt)
DE (1)	DE602004024821D1 (lt)
DK (1)	DK1687329T3 (lt)
ES (1)	ES2340287T3 (lt)
FR (1)	FR15C0081I2 (lt)
HU (1)	HUS1500064I1 (lt)
IL (1)	IL175353A (lt)
IS (1)	IS2741B (lt)
LT (1)	LTC1687329I2 (lt)
LU (1)	LU92901I2 (lt)
MY (1)	MY139500A (lt)
NL (1)	NL300775I2 (lt)
NO (2)	NO340633B1 (lt)
NZ (1)	NZ546697A (lt)
PL (1)	PL1687329T3 (lt)
PT (1)	PT1687329E (lt)
RU (1)	RU2370538C2 (lt)
SI (1)	SI1687329T1 (lt)
TW (1)	TWI332988B (lt)
WO (1)	WO2005047315A2 (lt)
ZA (1)	ZA200603106B (lt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7858098B2 (en) *	2002-12-20	2010-12-28	Glaxosmithkline Biologicals, S.A.	Vaccine
US8206950B2 (en) *	2003-06-09	2012-06-26	Animal Technology Institute Taiwan	Fusion antigen used as vaccine and method of making them
ATE466022T1 (de)	2004-03-24	2010-05-15	Merck Sharp & Dohme	Optimierte expression von hpv-52-l1 in hefe
US20070243587A1 (en) *	2006-04-14	2007-10-18	Healthbanks Biotech Co., Ltd.	Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus
CN101148661B (zh) *	2006-09-18	2013-01-02	中国医学科学院基础医学研究所	人***瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途
EP2129394B1 (en) *	2007-03-09	2012-06-20	Merck Sharp & Dohme Corp.	Papillomavirus vaccine compositions
DK2147926T3 (en)	2007-04-29	2016-11-28	Beijing Wantai Biological Pharmacy Entpr Co Ltd	Truncated human papillomavirus type 18 L1 protein
BRPI0811016B1 (pt)	2007-04-29	2021-09-21	Xiamen Innovax Biotech Co., Ltd.	Proteína li truncada do papiloma vírus humano tipo 16
CN101343315B (zh) *	2007-05-29	2012-06-13	厦门大学	截短的人***瘤病毒6型l1蛋白
CN101113417B (zh) *	2007-06-22	2011-04-27	山东大学	Hpv基因酵母体外翻译***的建立
CN101200696B (zh) *	2007-11-14	2011-07-20	山东大学	人***瘤病毒的酵母增殖模型及建立方法与应用
EP2223933B1 (en) *	2007-11-23	2016-01-27	Shanghai Zerun Biotechnology Co., Ltd.	Genes encoding major capsid protein l1 of human papilloma viruses
KR20090073987A (ko) *	2007-12-31	2009-07-03	정운원	인간유두종바이러스 유전자형 검사를 위한 프라이머, 프로브 및 이를 포함하는 ｄｎａ칩, 이의 검사 방법 및 검사 키트
CN106377767A (zh) *	2008-05-26	2017-02-08	卡迪拉保健有限公司	麻疹‑人***瘤组合疫苗
US9335868B2 (en) *	2008-07-31	2016-05-10	Apple Inc.	Capacitive sensor behind black mask
EP2576840B1 (en)	2010-05-25	2018-10-17	QIAGEN Gaithersburg, Inc.	Fast results hybrid capture assay and associated strategically-truncated probes
CN101857870B (zh) *	2010-06-12	2012-09-05	上海泽润生物科技有限公司	Hpv58 l1基因及载体、菌株和表达方法
WO2012006962A1 (zh) *	2010-07-16	2012-01-19	厦门大学	截短的人***瘤病毒58型l1蛋白
CN102154325B (zh) *	2011-01-01	2013-08-21	上海生物制品研究所有限责任公司	针对人***瘤状病毒的疫苗及其制法和用途
EP2722389B1 (en) *	2011-06-15	2018-03-07	Hong Jin Kim	Method for enhancing the production yield of human papillomavirus l1 protein
CN103361280B (zh) *	2012-03-28	2018-07-24	北京安百胜生物科技有限公司	用汉逊酵母表达***产生hpv11 l1蛋白的方法
EP2858680B1 (en)	2012-06-07	2018-10-31	The Children's Hospital of Philadelphia	Controlled gene expression methods
CN103992395B (zh) *	2013-02-18	2018-07-27	北京康乐卫士生物技术股份有限公司	重组hpv-58型l1的vlp疫苗及其制备方法
CN104120088B (zh) *	2013-04-26	2019-09-24	北京安百胜生物科技有限公司	用汉逊酵母表达***产生hpv58 l1蛋白的方法
CN104164373B (zh) *	2013-05-17	2019-04-02	北京安百胜生物科技有限公司	用汉逊酵母表达***产生hpv68l1蛋白的方法
CN104164374B (zh) *	2013-05-17	2019-10-22	北京安百胜生物科技有限公司	用汉逊酵母表达***产生hpv31 l1蛋白的方法
EP3057612B1 (en)	2013-10-16	2020-05-06	Merck Sharp & Dohme Corp.	Method of obtaining thermostable dried vaccine formulations
AU2015313756A1 (en) *	2014-09-11	2017-03-09	Cadila Healthcare Limited	Superior human papilloma virus antigens with superior immunological properties and vaccine containing it
CN117187263A (zh) *	2015-03-30	2023-12-08	上海泽润生物科技有限公司	重组人***瘤病毒33亚型蛋白表达
CN104878022A (zh) *	2015-04-27	2015-09-02	段青姣	编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用
WO2017092710A1 (zh) *	2015-12-04	2017-06-08	厦门大学	一种人***瘤病毒58型l1蛋白的突变体
BR112022015313A2 (pt)	2020-02-14	2022-09-27	Merck Sharp & Dohme Llc	Vacina de hpv
CN113073105B (zh) *	2021-03-23	2023-06-13	重庆博唯佰泰生物制药有限公司	一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用
CN113549634B (zh) *	2021-06-07	2023-03-31	郑州大学	编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用
TW202313658A (zh)	2021-08-06	2023-04-01	美商默沙東有限責任公司	Hpv疫苗
TW202315602A (zh)	2021-08-19	2023-04-16	美商默沙東有限責任公司	新穎熱穩定脂質奈米粒子及其使用方法
CN117054647A (zh) *	2023-07-17	2023-11-14	广东省一鼎生物技术有限公司	一种检测HPV IgG抗体试剂盒及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5821087A (en)	1995-03-30	1998-10-13	Merck & Co., Inc.	Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA
IL117591A0 (en)	1995-03-30	1996-07-23	Merck & Co Inc	Synthetic DNA encoding human papillomavirus type 11 L1 protein
DE69836206T2 (de)	1997-02-07	2007-08-23	Merck & Co., Inc.	Synthetische hiv gag gene
EP1002091B1 (en)	1997-07-09	2012-02-29	Coridon Pty Limited	Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
EP1105157B1 (en)	1998-08-14	2006-11-02	Merck & Co., Inc.	Protein delivery system using human papillomavirus virus-like particles
ES2262333T3 (es) *	1998-08-14	2006-11-16	MERCK & CO., INC.	Procedimiento para purificar particulas similares a virus de papilomavirus humano.
SE514982C2 (sv) *	1999-09-30	2001-05-28	Active Biotech Ab	Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
DE60016765T2 (de) *	1999-08-25	2005-11-24	Merck & Co., Inc.	Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
US6436402B1 (en) *	1999-10-15	2002-08-20	Merck & Co., Inc.	Process for making human papillomavirus virus-like particles with improved properties
US7026443B1 (en) *	1999-12-10	2006-04-11	Epimmune Inc.	Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
BR0112637A (pt)	2000-07-21	2003-06-10	Glaxo Group Ltd	Sequências do vìrus do papiloma códon-otimizadas
AU2003219760A1 (en) *	2002-02-14	2003-09-04	Novavax, Inc.	Optimization of gene sequences of virus-like particles for expression in insect cells
EP1608767B1 (en) *	2003-03-24	2012-02-22	Merck Sharp & Dohme Corp.	Optimized expression of hpv 31 l1 in yeast
MY140664A (en)	2003-09-29	2010-01-15	Merck Sharp & Dohme	Optimized expression of hpv 45 l1 in yeast

2004
- 2004-11-09 MY MYPI20044678A patent/MY139500A/en unknown
- 2004-11-10 US US10/579,111 patent/US7498036B2/en active Active
- 2004-11-10 AT AT04810619T patent/ATE452977T1/de active
- 2004-11-10 KR KR1020067009199A patent/KR101170654B1/ko active Protection Beyond IP Right Term
- 2004-11-10 EP EP04810619A patent/EP1687329B8/en active Active
- 2004-11-10 SI SI200431328T patent/SI1687329T1/sl unknown
- 2004-11-10 ES ES04810619T patent/ES2340287T3/es active Active
- 2004-11-10 WO PCT/US2004/037372 patent/WO2005047315A2/en active Application Filing
- 2004-11-10 RU RU2006120402/13A patent/RU2370538C2/ru active
- 2004-11-10 DK DK04810619.9T patent/DK1687329T3/da active
- 2004-11-10 NZ NZ546697A patent/NZ546697A/en unknown
- 2004-11-10 CA CA2543928A patent/CA2543928C/en active Active
- 2004-11-10 BR BRPI0416393-1A patent/BRPI0416393B1/pt active IP Right Grant
- 2004-11-10 PT PT04810619T patent/PT1687329E/pt unknown
- 2004-11-10 AR ARP040104141A patent/AR046835A1/es active IP Right Grant
- 2004-11-10 AU AU2004290032A patent/AU2004290032B2/en active Active
- 2004-11-10 JP JP2006539751A patent/JP4912885B2/ja active Active
- 2004-11-10 DE DE602004024821T patent/DE602004024821D1/de active Active
- 2004-11-10 PL PL04810619T patent/PL1687329T3/pl unknown
- 2004-11-10 CN CN2004800332355A patent/CN1942583B/zh active Active
- 2004-11-11 TW TW093134524A patent/TWI332988B/zh active
2006
- 2006-04-19 ZA ZA200603106A patent/ZA200603106B/en unknown
- 2006-04-21 IS IS8425A patent/IS2741B/is unknown
- 2006-05-01 IL IL175353A patent/IL175353A/en active IP Right Grant
- 2006-06-09 NO NO20062674A patent/NO340633B1/no active Protection Beyond IP Right Term
2009
- 2009-01-26 US US12/321,797 patent/US7976848B2/en active Active
2010
- 2010-03-19 CY CY20101100258T patent/CY1113875T1/el unknown
2011
- 2011-12-08 JP JP2011268598A patent/JP5616879B2/ja active Active
2015
- 2015-11-30 NL NL300775C patent/NL300775I2/nl unknown
- 2015-12-02 HU HUS1500064C patent/HUS1500064I1/hu unknown
- 2015-12-04 FR FR15C0081C patent/FR15C0081I2/fr active Active
- 2015-12-07 CY CY2015051C patent/CY2015051I1/el unknown
- 2015-12-08 LT LTPA2015048C patent/LTC1687329I2/lt unknown
- 2015-12-08 LU LU92901C patent/LU92901I2/xx unknown
- 2015-12-09 BE BE2015C070C patent/BE2015C070I2/nl unknown
2017
- 2017-11-10 NO NO2017058C patent/NO2017058I1/no unknown

Also Published As

Publication number	Publication date
MY139500A (en)	2009-10-30
SI1687329T1 (sl)	2010-03-31
CA2543928C (en)	2011-04-05
CA2543928A1 (en)	2005-05-26
BE2015C070I2 (lt)	2023-12-18
US20100272749A1 (en)	2010-10-28
ZA200603106B (en)	2007-09-26
TWI332988B (en)	2010-11-11
JP2008500019A (ja)	2008-01-10
NL300775I1 (lt)	2015-12-29
US20070036824A1 (en)	2007-02-15
LU92901I2 (fr)	2016-03-08
CY2015051I2 (el)	2016-06-22
NZ546697A (en)	2009-05-31
IS8425A (is)	2006-04-21
CY2015051I1 (el)	2016-06-22
HUS1500064I1 (hu)	2016-02-29
EP1687329B8 (en)	2010-03-17
CN1942583B (zh)	2010-10-27
WO2005047315A2 (en)	2005-05-26
DK1687329T3 (da)	2010-04-12
CY1113875T1 (el)	2016-06-22
ES2340287T3 (es)	2010-06-01
JP5616879B2 (ja)	2014-10-29
NO20062674L (no)	2006-06-09
RU2370538C2 (ru)	2009-10-20
IS2741B (is)	2011-06-15
PL1687329T3 (pl)	2010-06-30
IL175353A (en)	2010-11-30
AU2004290032B2 (en)	2009-02-05
EP1687329A2 (en)	2006-08-09
FR15C0081I2 (fr)	2016-11-25
NO2017058I1 (no)	2017-11-10
US7976848B2 (en)	2011-07-12
ATE452977T1 (de)	2010-01-15
WO2005047315A3 (en)	2006-09-28
EP1687329B1 (en)	2009-12-23
BRPI0416393B1 (pt)	2021-06-29
KR20060122852A (ko)	2006-11-30
NO340633B1 (no)	2017-05-15
AU2004290032A1 (en)	2005-05-26
DE602004024821D1 (de)	2010-02-04
TW200519203A (en)	2005-06-16
BRPI0416393A (pt)	2007-04-03
PT1687329E (pt)	2010-02-26
CN1942583A (zh)	2007-04-04
JP2012095652A (ja)	2012-05-24
JP4912885B2 (ja)	2012-04-11
RU2006120402A (ru)	2007-12-27
KR101170654B1 (ko)	2012-08-03
AR046835A1 (es)	2005-12-28
NL300775I2 (lt)	2015-12-29
FR15C0081I1 (fr)	2016-08-01
US7498036B2 (en)	2009-03-03
IL175353A0 (en)	2006-09-05

Publication	Publication Date	Title
LTC1687329I2 (lt)	2017-05-10	Optimizuotos HPV58 L1 raiška mielėse
LTC1673106I2 (lt)	2017-05-10	ŽPV 45 L1 optimizuota ekspresija mielėse
LTC1730175I2 (lt)	2017-05-10	Optimizuota HPV 52 L1 raiška mielėse
DE602004000432D1 (de)	2006-04-27	Touchscreen
DK1829959T3 (da)	2013-07-08	Rekombinant mikroorganisme
FI20045149A (fi)	2005-10-24	Käyttöliittymä
EP1766073A4 (en)	2007-08-01	IMPROVING PROTEIN EXPRESSION
DE602004022088D1 (de)	2009-08-27	Zellkultivierungskolben
DK1689869T3 (da)	2011-02-07	Rekombinant mikroorganisme
ITPI20040084A1 (it)	2005-02-18	Interfaccia aptica portabile
DK1680502T3 (da)	2011-03-07	Rekombinant mikroorganisme
NO20040180L (no)	2005-05-12	Stol
ES1054906Y (es)	2003-12-16	Medios de sustentacion de vidrios en correderas de bañeras.
SE0402778L (sv)	2006-05-13	Stol
SE0301957L (sv)	2004-01-11	Stol
DE502004007042D1 (de)	2008-06-19	Sonnensensor
ITFI20030193A1 (it)	2005-01-18	Lievito per vinificazione.
DE602004015963D1 (de)	2008-10-02	Rke
ITVI20030127A1 (it)	2005-01-02	Solaio in latero - cemento.
FI20030035A0 (fi)	2003-01-10	Puskuri
NO20035014D0 (no)	2003-11-11	Stol
ITPI20030083A1 (it)	2005-04-28	Bottale con perfezionamenti costruttivi adatti, in
UA8034S (uk)	2003-10-15	Губка
ITPR20030086A1 (it)	2005-04-04	Procedimento per realizzare scope in particolare
ES1054922Y (es)	2003-12-16	Trituradora-cosechadora de maleza y similares.